Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis

Modern Rheumatology

Volumn 22, Issue 1, 2012, Pages 109-115

  Imagawa, Tomoyuki ^a   Yokota, Shumpei ^a   Mori, Masaaki ^a   Miyamae, Takako ^a   Takei, Syuji ^b   Imanaka, Hiroyuki ^b   Nerome, Yasuhito ^b   Iwata, Naomi ^c   Murata, Takuji ^d   Miyoshi, Mari ^e   Nishimoto, Norihiro ^f   Kishimoto, Tadamitsu ^g  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c AICHI CHILDREN'S HEALTH AND MEDICAL CENTER   (Japan)

^d OSAKA MEDICAL COLLEGE   (Japan)

^e KOBE CHILDREN S HOSPITAL   (Japan)

^f WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^g OSAKA UNIVERSITY   (Japan)

Author keywords

Interleukin 6 (IL 6); Juvenile idiopathic arthritis; Tocilizumab

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; MONOCLONAL ANTIBODY; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; CAMPYLOBACTERIOSIS; CHILD; CLINICAL ARTICLE; DEATH; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROENTERITIS; HEART FAILURE; HUMAN; INSECT BITE; JUVENILE RHEUMATOID ARTHRITIS; LUNG TUBERCULOSIS; MALE; MULTICENTER STUDY; MYCOPLASMOSIS; OPEN STUDY; PHARYNGITIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; RHINOPHARYNGITIS; SCHOOL CHILD; SENSORY DYSFUNCTION; SIDE EFFECT; STOMATITIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; METHOTREXATE; RECEPTORS, INTERLEUKIN-6; REMISSION INDUCTION; TREATMENT FAILURE; YOUNG ADULT;

EID: 84861479447     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0481-0     Document Type: Article

References (22)

1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, International League of Associations for Rheumatology, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390-2. (Pubitemid 38160763)
2. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med. 1992;326:1043-9.
3. Reiff A, Shaham B, Wood BP, Bernstein BH, Stanley P, Szer IS. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol. 1995;13:113-8.
4. Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43:1849-57.
5. Wallace CA. The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum. 1998;41:381-91. (Pubitemid 28128761)
6. Grom AA, Murray KJ, Luyrink L, Emery H, Passo MH, Glass DN, et al. Patterns of expression of tumor necrosis factor a, tumor necrosis factor β, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondyloarthropathy. Arthritis Rheum. 1996;39:1703-10. (Pubitemid 26331024)
7. De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34:1158-63.
8. De Benedetti F, Robbioni P, Massa M, Viola S, Albani S, Martini A. Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis. Clin Exp Rheumatol. 1992;10:493-8.
9. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Pediatric Rheumatology Collaborative Study Group, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763-9. (Pubitemid 30151920)
10. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58:1496-504. (Pubitemid 351705939)
11. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48(4): 1093-101. (Pubitemid 36418252)
12. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1):12-9.
13. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106: 2627-32. (Pubitemid 41510733)
14. Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum. 2002;46:3388-9. (Pubitemid 35453552)
15. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled, withdrawal phase III trial. Lancet. 2008;371: 998-1006. (Pubitemid 351389534)
16. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202-9. (Pubitemid 27430130)
17. van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49:916-20. (Pubitemid 20360757)
18. Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PL, et al. Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
19. van Gestel AM, Prevoo MLL, van't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PL, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum. 1996;39:34-40. (Pubitemid 26036375)
20. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112: 3959-64.
21. Stastny P, Fernandez-Vina M, Cerna M, Havelka S, Ivaskova E, Vavrincova P. Sequences of HLA alleles associated with arthritis in adults and children. J Rheumatol Suppl. 1993;37:5-8. (Pubitemid 23128474)
22. Okubo H, Itou K, Tanaka S, Watanabe N, Kashiwagi N, Obata F, et al. Analysis of the HLA-DR gene frequencies in Japanese cases of juveniles rheumatoid arthritis and rheumatoid arthritis by oligonucleotide DNA typing. Rheumatol Int. 1993;13:65-9. (Pubitemid 23247816)